Key Points {#FPar1}
==========

This initial study to determine the prevalence of adverse drug reactions (ADRs) in two hospitals in Myanmar found that almost one-third of the participating hospitalised patients presented with an unwanted effect.One-quarter of the observed ADRs were associated with only three ADR--medicine combinations. Additionally, more than one-half of the identified ADRs in the study sample were considered preventable effects. Thus, increased awareness of pharmacovigilance could avoid many such cases and increase patient safety.Six patients presented an ADR attributed to herbal remedies. Pharmacovigilance in settings with a high use of such traditional remedies should include clear guidance on their potential toxicity.

Introduction {#Sec1}
============

Multiple studies have emphasised the high prevalence and potential seriousness of adverse drug reactions (ADRs), especially among aged patients and those receiving polypharmacy. ADRs are especially relevant in hospitalised patients, with one meta-analysis reporting an estimated 6.7% of hospitalised patients in the USA developing a serious unwanted effect and a fatality rate of 0.32% \[[@CR1]\]. In the USA, an estimated 2,216,000 serious ADRs occurred in hospitalised patients and caused over 106,000 deaths in 1994 \[[@CR1]\]. According to a European Commission report, 3--10% of hospital admissions between 2012 and 2014 were caused by ADRs, totalling about 2.5--8.4 million annually, and 2.1--6.5% of hospitalised patients experienced an ADR, corresponding to 1.8--5.5 million annually \[[@CR2]\].

On the other hand, most emergency hospitalisations for recognised ADRs in older adults resulted from a few commonly used medications \[[@CR3]\], suggesting that understanding of pharmacovigilance, awareness of potential ADRs, and identification of patients at risk could help prevent many of these situations, which prompt emergency admissions or complicate the clinical course of already hospitalised patients.

In 1968, the World Health Organization (WHO) established its Programme for International Drug Monitoring in response to the thalidomide disaster \[[@CR4]\]; 136 countries are now full members and 29 are associate members of this programme. In 2018, Myanmar became an associate member \[[@CR5]\]. Thus, the pharmacovigilance programme in Myanmar is at a very preliminary stage, although Myanmar's ADR reporting system was established in 2002 and the Myanmar Food and Drug Administration (FDA) has distributed an ADR reporting form to central, state, and regional hospitals; health offices; and drug advisory committee members. An implementation research report by postgraduate students and specialist clinicians from eight teaching hospitals under University of Medicine 1, Yangon, found that 44.9% of respondents had poor awareness of the ADR reporting system and that several barriers to ADR reporting existed \[[@CR6]\]. Another study conducted in eight teaching hospitals in Yangon showed that most assistant surgeons were not aware of the ADR reporting system (79.3%), the ADR reporting form (89.7%), or the department to which ADRs should be reported (83.3%) \[[@CR7]\].

A prospective observational study conducted for antimycobacterial drugs in a tuberculosis campaign in Myanmar found that 115 of 128 patients (88.3%) experienced ADRs, and a total of 349 adverse effects were reported in 6 months \[[@CR8]\].

To initiate a drug safety strategy for Myanmar, the first step is to provide evidence that ADRs are frequent in the country and to raise awareness among health professionals and drug authorities about the frequent complications of medical treatment. Therefore, the present study aimed to describe ADRs leading to hospital admission or occurring in patients admitted to selected wards of Yangon General Hospital (YGH) and Yangon Specialty Hospital (YSH).

Methods {#Sec2}
=======

A prospective observational study was designed and conducted in one medical and one surgical ward in YGH and one rheumatology ward in YSH between 1st January and 31st March 2019. YGH is a 1500-bed hospital and one of the biggest teaching hospitals in Myanmar, and YSH is a 500-bed hospital; both hospitals admit adult patients (aged \> 12 years according to the country's clinical classification). All patients admitted to the wards under study in YGH and YSH during the study period were identified during the first 24 h after admission to be followed-up until hospital discharge or day 28 after admission.

Exclusion criteria were any patients who took an overdose (deliberately or not), were critically ill (unstable vital signs, tracheotomy, or mechanical ventilation), were unable to understand and answer questions (i.e., could not speak Myanmar), or refused to participate or withdrew from the study.

Researchers were trained in how to identify ADRs, complete the reporting form (see the online Appendix), and review patients' treatment charts and laboratory test results, and were given resources describing common ADRs. Researchers were also trained in how to use the assessment tools adopted for the present study. A workshop was conducted to ensure researchers used diagnostic criteria and applied the algorithms consistently.

Potential study participants were given a full explanation of objectives, procedures, benefits, and possible risks of the study. Patients who were willing to participate in the study provided written informed consent; one patient refused to participate (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flowchart describing the patient selection and follow-up process (see Methods). *ADR* adverse drug reaction, *YGH* Yangon General Hospital, *YSH* Yangon Specialty Hospital

All included patients attended a face-to-face interview during which they were asked about suspected ADRs, and researchers reviewed patients' clinical charts and laboratory test results. Researchers (14 clinical pharmacologists from the University of Medicine 1, Yangon) visited the study ward daily to identify any suspected ADRs in the recruited patients during a 4-week period (28 days). All clinical staff were officially informed that a study on ADRs was taking place. If patients were transferred to another ward, the researchers followed them and continued observations for ADRs. If the patient was discharged from hospital, the researcher phoned them daily until the end of the follow-up period (day 28 after admission) to check for the occurrence of any ADR.

An ADR was defined according to the classical WHO definition ("Any response to a drug which is noxious, unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function") \[[@CR4]\]. All identified suspected ADRs were discussed by the study team of clinicians and pharmacologists weekly. The British National Formulary and specific bibliographic websites were used to assess previous knowledge about the identified ADRs. Each suspected ADR was classified according to the WHO-Adverse Reactions Terminology (ART) dictionary. Causality was assessed using the Naranjo algorithm \[[@CR9]\]. The severity of the ADR was also categorised according to the Hartwig severity scale \[[@CR10]\], and preventability was assessed using the Schumock and Thornton preventability scale \[[@CR11]\]. Polypharmacy was defined as more than five drugs being taken concomitantly by a single patient, and 'increased transaminase' was used when the transaminase level was at least 1.5 times higher than the upper normal reference value given by the hospital laboratory.

Data Analysis {#Sec3}
-------------

Continuous variables were presented as means ± standard deviations, and categorical variables were presented as number and percentage. The variables were compared between patients with ADRs and those without ADRs using descriptive statistical tests, the independent samples *t* test for continuous variables, and the Chi-squared test for categorical variables. Binary logistic regression (univariate and multivariate analysis using a forward conditional method) was performed to examine possible associations between ADR occurrence and different variables. Possible confounders were adjusted for (age, sex, type of wards, comorbidities, liver and renal diseases), and the results were presented as odds ratios (ORs) with 95% confidence intervals (CIs). The reported *p* values are two-tailed, and an *α* level of 0.05 was used to assess statistical significance. SPSS version 20 was used for data entry and analysis.

Results {#Sec4}
=======

During the study period, 160 patients admitted to the selected wards of YGH and YSH gave informed consent to be monitored for potential adverse effects up to 28 days after admission. Almost one-half (77 \[48.1%\]) were admitted to the medical ward, 59 (36.9%) to the surgical ward, and 24 (15.0%) to the rheumatology ward.

A total of 65 ADRs were identified in 47 patients; 29.4% of patients admitted to these selected wards presented at least one suspected ADR. In 16 of these patients (one ADR each), the adverse effect was what led to admission; the remaining 49 ADRs appeared in 31 patients during their hospital stay (48 ADRs) or after discharge and before day 28 (one ADR). Table [1](#Tab1){ref-type="table"} shows the characteristics of all the recruited patients and the subsample of patients presenting one or more ADRs. The mean age of recruited patients was 46.7 ± 17.2 years; patients who presented an ADR were younger than those who did not. The initial sample of patients included 93 women (58.1%) and 67 men (41.9%), and a significantly higher proportion of women presented an ADR. Patients presenting an ADR took significantly more medications (12.15 ± 6.12) than those without ADRs (7.99 ± 4.15). No differences were seen in incidence of comorbidities and liver disease between patients with and without ADRs, but a higher proportion of those presenting a suspected ADR had renal disease.Table 1Characteristics of patients admitted to the medical, surgical, and rheumatology units of the included hospitals presenting at least one ADR (*n* = 47) and those not presenting ADRs (*n* = 113)VariableADRs*t* test*p* value (independent sample *t* test)PresentAbsentTotalAge (years)40.8 ± 17.649.2 ± 16.546.7 ± 17.2− 2.8620.005\*No. of medications12.15 ± 6.127.99 ± 4.159.21 ± 5.164.982\< 0.001\*VariableADRsOR (95% CI)*p* (Chi-squared)PresentAbsentTotalAge (years) \< 6037 (32.5)77 (67.5)114 (100.0)1.730 (0.775--3.861)0.178 ≥ 6010 (21.7)36 (78.3)46 (100.0)Sex Male10 (14.9)57 (85.1)67 (100.0)0.266 (0.121--0.585)\< 0.001\*\* Female37 (39.8)56 (60.2)93 (100.0)Ward Rheumatology17 (70.8)7 (29.2)24 (100.0)0.135 (0.049--0.375)\< 0.001\*\* Surgical11 (18.6)48 (81.4)59 (100.0)1.429 (0.620--3.296)0.402 Medical19 (24.7)58 (73.5)77 (100.0)Comorbidity Present20 (27.8)52 (72.2)72 (100.0)0.869 (0.437--1.726)0.688 Absent27 (30.7)61 (69.3)88 (100.0)Liver disease Present2 (14.3)12 (85.7)14 (100.0)0.374 (0.080--1.741)0.194 Absent45 (30.8)101 (69.2)146 (100.0)Renal disease Present9 (56.3)7 (43.8)16 (100.0)3.586 (1.249--10.300)0.013\*\* Absent38 (26.4)106 (73.6)144 (100.0)Data are presented as mean ± standard deviation or *N* (%) unless otherwise indicated*ADR* adverse drug reaction, *CI* confidence interval, *OR* odds ratio, *SD* standard deviation\*Independent sample *t* test, *p* \< 0.001\*\*Binary logistic regression, *p* \< 0.05

The distribution of patients with ADRs in the different wards was as follows: 19 in the medical unit (24.7% of patients admitted to that ward), 17 in the rheumatology unit (70.8% of the patients admitted to that ward), and 11 in the surgical unit (18.6% of those admitted in that ward). The multivariate analysis showed statistically significant differences in the proportion of ADRs identified in the different wards, with the highest proportion in rheumatology (OR 0.214 \[95% CI 0.072--0.632\]; *p* \< 0.0001) (see Table [2](#Tab2){ref-type="table"}).Table 2Adjusted odds ratio for a multiple logistic regression model taking into account the presence or absence of adverse drug reactions, the wards where patients had been admitted, and the total number of medications receivedVariableADRAdjusted OR (95% CI)*p* valuePresentAbsentWards Rheumatology17 (70.8)7 (29.2)0.214 (0.072--0.632)0.005 Surgical11 (18.6)48 (81.4)1.111 (0.463--2.664)0.814 Medical19 (24.7)58 (73.5)Medications (*n*)12.15 ± 6.127.99 ± 4.150.888 (0.817--0.965)0.005The model correctly classifies 76.9% of cases. The Chi-squared value associated with the Hosmer--Lemeshow (Chi-squared = 7.386, *df* = 8, *p* = 0.496) indicates a good overall model fit. Data are presented as mean ± standard deviation or *N* (%) unless otherwise indicated*ADR* adverse drug reaction, *CI* confidence interval, *OR* odds ratio

Up to 61 ADRs could be attributed to 28 different medicines and six herbal remedies, whereas the causal medicine could not be clearly identified in four ADRs because of the concomitant use of different medicines (Table [3](#Tab3){ref-type="table"}). The therapeutic groups most associated with these ADRs were corticosteroids (16 \[29.1%\]), nonsteroidal anti-inflammatory drugs (NSAIDs; 8 \[14.4%\]); opioids (7 \[12.7%\]); and antibacterials (6 \[10.8%\]). Table [3](#Tab3){ref-type="table"} summarizes the six herbal remedies suspected to have caused six of the ADRs.Table 3Classification of the suspected medicines involved in the 65 ADRs identified in the different wards of the included hospitalsMedicines, therapeutic groupActive ingredient (*n*)ADRsCorticosteroidsMethylprednisolone (12)16 (29.1)Prednisolone (4)NSAIDsAspirin (80 mg) (2)8 (14.4)Diclofenac (2)Other NSAIDs (4)OpioidsTramadol (4)7 (12.7)Codeine (1)Nalbuphine (2)Antibacterial agentsLevofloxacin (3)6 (10.8)Other (3)Antimycobacterial drugsHRZE (4)4 (7.3)Drugs used in rheumatologyCyclophosphamide (3)4 (7.3)Hydroxychloroquine (1)Cardiovascular drugsACEIs and CCBs (2)3 (5.5)Isosorbide mononitrate (1)Blood disordersWarfarin (2)3 (5.5)Tranexamic acid (1)Other^a^4 (7.3)Total patients with ADRs caused by drugs55 (100)ADRs in patients receiving more than one drug^b^4ADRs in patients taking herbal remedies Pan Wut Hmone (increased transaminase)1 Myat Thu Kha (increased transaminase)1 Tha Hmar Ni (increased transaminase)1 Chan Saint (haematemesis and melena)1 Kyar Pyan (haematemesis and melena)1 Unknown (congestive heart failure)1Total ADRs in patients taking herbal remedies6ADRs are presented as *n* (%). 55 ADRs were attributed to single drugs, four ADRs were diagnosed in patients receiving more than one medicine and the causal medicine could not be clearly identified; six ADRs were attributed to herbal remedies*ACEIs* angiotensin-converting enzyme inhibitors, *ADR* adverse drug reaction, *CCBs* calcium channel blockers, *HRZE* isoniazid + rifampicin + pyrazinamide + ethambutol, *NSAID* nonsteroidal anti-inflammatory drug^a^One patient each: insulin, mesna, ranitidine, potassium chloride^b^The four ADRs diagnosed in patients treated with more than one medicine, and the causal one could not be identified: (1) a combination of frusemide and methylprednisolone was associated with hypokalaemia; (2) levofloxacin, perindopril, and statin associated with increased transaminase levels; (3) sulbactam, cefoperazone, metronidazole, and azithromycin associated with gastrointestinal disturbance; and (4) valproate and leflunomide associated with increased transaminase levels

More than one-third of the suspected ADRs (23 \[35.4%\]) involved the gastrointestinal system, 14 (21.5%) were blood and electrolyte disturbances, ten (15.4%) were liver disorders, and eight (12.3%) were classified as 'general ADRs' according to the WHO-ART dictionary. The most frequent individual ADRs identified were increased transaminase levels in ten patients (four taking standard antimycobacterial drugs, three taking herbal remedies, two taking a combination of drugs, and one taking ranitidine). Nine patients presented nausea/vomiting (13.8%) associated with diverse medicines, seven patients presented hypokalaemia (five of which were after receiving methylprednisolone), five were diagnosed with upper gastrointestinal bleeding, and two had perforated peptic ulcers (Table [4](#Tab4){ref-type="table"}).Table 4Association between ADR and suspected medicine in the 65 ADRs observed in this studyOrgan/system*N* (%)Suspected ADRs*n*Associated drugs (*n*)Digestive23 (35.4)Nausea/vomiting9Levofloxacin (2)Cyclophosphamide (2)Codeine (1)Ketorolac (1)Nalbuphine (1)Tramadol (1)Combined medicines^a^ (1)Constipation4Tramadol (3)Diclofenac (1)Upper gastrointestinal bleeding5NSAID (2)Herbal remedy (2)ASA (80 mg) (1)Peptic ulcer perforation2NSAIDs (2)Gastritis1Prednisolone (1)Loss of appetite1Cyclophosphamide (1)Loose stools1Piperacillin (1)Blood14 (21.5)Hypokalaemia7Methylprednisolone (5)Insulin (1)Combined medicines^a^ (1)Increased INR2Warfarin (2)Bruise2Aspirin (1)Methylprednisolone (1)Hyperglycaemia1Methylprednisolone (1)Hyperkalaemia1Potassium chloride (1)Leucocytosis1Prednisolone (1)Liver10 (15.4)Increased transaminase level10HRZE (4)Herbal remedy (3)Combined medicines^a^ (2)Ranitidine (1)General8 (12.3)Chill1Mesna (1)Dizziness3Nalbuphine (1)Cilnidipine (1)Metronidazole (1)Headache2Cefepime (1)Isosorbide mononitrate (1)Proximal myopathy1Prednisolone (1)Sore throat1Methylprednisolone (1)Respiratory4 (6.2)Dry cough1Enalapril (1)Chest infection3Prednisolone (1)Methylprednisolone (2)Skin3 (4.6)Itchiness (2)2Levofloxacin (1)Tranexamic acid (1)Poor wound healing (1)1Methylprednisolone (1)Eyes2 (3.1)Blurred vision1Hydroxychloroquine (1)Glaucoma1Steroid (1)Cardiovascular1 (1.5)Congestive heart failure1Herbal remedy (1)Each patient can present more than one ADR; one medicine can produce more than one ADR*ADR* adverse drug reaction, *ASA* acetylsalicylic acid, *HRZE* isoniazid, rifampicin, pyrazinamide, ethambutol, *INR* international normalised ratio, *NSAIDs* nonsteroidal anti-inflammatory drugs^a^Combined medicines: (1) a combination of frusemide and methylprednisolone was associated with hypokalaemia; (2) levofloxacin, perindopril, and statin was associated with increased transaminase levels; (3) sulbactam, cefoperazone, metronidazole, and azithromycin were associated with gastrointestinal disturbances, and (4) valproate and leflunomide were associated with increased transaminase levels

The most frequent ADRs-suspected drug combinations in the present study were low potassium levels in five patients receiving methylprednisolone, four patients with increased liver enzymes levels receiving antimycobacterial drugs, three patients with upper gastrointestinal bleeding receiving an NSAID or low-dose aspirin, three patients with constipation receiving tramadol, and three patients with increased transaminase levels receiving herbal remedies. These five pairs of ADR--suspected drugs represented more than one-quarter of the 65 ADRs identified in this study.

Causality assessment of the 65 identified ADRs according to the Naranjo algorithm showed five 'definite' (7.7%), 27 'probable' (41.5%), and 33 (50.8%) 'possible' associations. According to the Hartwig severity scale, 45 ADRs required some action (69.2%) and 20 required no change in treatment (30.8%). Among the 45 ADRs requiring some action, 20 received another treatment (44.4%); 16 (35.5%) led to hospital admission; six (13.3%) required treatment with the suspected drug to be held, discontinued, or otherwise changed; and three (6.7%) prolonged the hospital stay.

Analysis with the Schumock preventability scale identified the ADRs that could have been avoided. More than one-half of the ADRs either definitely or probably could have been prevented (25 \[38.5%\] and 10 \[15.4%\], respectively). A few of these preventable ADRs were potentially severe: at least five cases of hypokalaemia associated with methylprednisolone, three cases of gastrointestinal bleeding associated with NSAIDs, three cases of increased transaminase levels, and two of gastrointestinal bleeding after taking a traditional medicine.

As noted, admission of 16 of these 160 patients was prompted by an ADR (10% of the study sample): six cases of increased liver enzymes (four caused by HRZE \[isoniazid + rifampicin + pyrazinamide + ethambutol\] and two attributed to herbal remedies), five gastrointestinal bleeding (two attributed to NSAIDs, two to herbal remedies, and one to low-dose aspirin), two gastric ulcer perforations associated with NSAIDs, one heart failure attributed to a traditional medicine, one hyperglycaemia due to methylprednisolone, and one prednisolone-induced chest infection.

Discussion {#Sec5}
==========

The present active pharmacovigilance study conducted in two hospitals in Yangon, Myanmar, showed that, in the selected wards, 29.4% of the admitted patients were diagnosed as having at least one ADR, either prompting the admission (16 patients \[10%\]) or complicating their hospitalisation (31 patients \[19%\]). A systematic review and meta-analysis published in 2017 showed a wide range of ADR prevalence in inpatients in Western countries, ranging from 3.9 to 57.9% in 12 studies \[[@CR12]\]. A 3-month study conducted in Singapore General Hospital, a 1600-bed tertiary teaching hospital, reported the prevalence of all ADRs at admission to be 12.4% (95% CI 10.5--14.6) and of ADRs causing admission to be 8.1% (95% CI 6.5--10.0); the most common ADRs were related to the gastrointestinal system, and cardiovascular drugs were the most frequently involved drugs \[[@CR13]\].

Two-thirds of the ADRs in the current study required some action from health professionals to be stopped or cured, thus suggesting that awareness of the adverse effects of drugs and potentiating of pharmacovigilance in hospitals is important to improve not only quality of care but also patient safety. Last, but not least, according to the Schumock preventability scale, more than one-half of these ADRs could have been avoided, another reason to consider these results as a starting point to raise awareness of the important role of hospital pharmacovigilance, one of the cornerstones of a national pharmacovigilance programme.

ADRs can be undiagnosed unless a health professional specifically asks about them. If not identified as an ADR, these symptoms easily become candidates for cascade treatments, which lead to polypharmacy, potential drug--drug interactions, and additional ADRs \[[@CR14]\]. Since ADRs sometimes hide behind common presenting symptoms and occasionally present bizarrely, a good anamnesis will help identify these hidden ADRs. In both situations, knowledge of pharmacovigilance, the pharmacovigilance system, and how to report suspected ADRs is important \[[@CR15]\].

The present study showed that one surgical ward, one medical ward, and one speciality ward are suitable places to study the prevalence of ADRs because almost all hospitals in our country contain surgical and medical wards, so both wards can represent most hospitals. One speciality ward was added to explore the prevalence of suspected ADRs in such a ward.

Our findings indicated that 29.4% of patients were either admitted because of an ADR or developed an ADR during hospitalisation. The prevalence of ADRs in the present study was high, but it should be remembered that researchers performed an active search for ADRs and that the reporting system is not well practised in Myanmar. Therefore, data on the incidence of ADRs are also scant. A study conducted in eight tertiary care teaching hospitals in Yangon showed that 48.1% of the postgraduate students (who were training to become specialist clinicians) had never heard of ADRs, 91.4% had not seen the Myanmar ADR reporting form, and 82.8% did not know which department an ADR should be reported to \[[@CR6]\]. Therefore, the main barriers to ADR reporting seem to be related to the awareness of ADRs, as has been described in other countries \[[@CR15]\].

Three ADR-suspect drug pairs accounted for almost one-quarter of the identified ADRs, found in one-third of the patients included in the study sample. These cases and a few other identified ADRs were well-known and, according to the Schumock and Thornton scale \[[@CR11]\], potentially avoidable. These findings agree with those of other larger studies conducted in other countries, which also described a concentration of ADRs in a few well-known unwanted effects produced by some common medicines \[[@CR3]\]. Prevention in pharmacovigilance is very important to increase patient safety and the quality of healthcare.

Conclusions {#Sec6}
===========

The present study was conducted in two tertiary care university hospitals of Yangon during the first quarter of 2019. Therefore, the figures obtained cannot be extrapolated to other hospitals or even to the rest of the country. Notwithstanding this limitation, the suspected ADRs actually happened. Therefore, the study achieved the main objective of providing evidence to participating hospitals that ADRs do occur, a first step to increasing awareness of drug safety and strengthening pharmacovigilance in Myanmar.
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